In this article, we will discuss 7 Best Longevity and Anti-Aging Stocks to Buy.
The next frontier of human health may not be found in a hospital; it may be unlocked in a laboratory. That’s the audacious premise behind longevity and anti-aging stocks, a sector drawing serious capital from billionaire investors, sovereign wealth funds, and life sciences-focused institutions positioning ahead of what could be the most consequential medical breakthrough cycle of the century. And unlike oncology or GLP-1s, this is not yet a crowded trade. It’s an emerging scientific frontier where the upside is potentially generational, but only for those who can separate genuine biological innovation from headline noise.
The investment case is being driven by demographics and data in equal measure. An aging global population, rising chronic disease burden, and the compounding cost of late-stage healthcare are creating immense structural pressure on traditional medicine to shift from treatment to prevention. Longevity science, spanning senolytics, epigenetic reprogramming, NAD+ metabolism, and mTOR pathway intervention, offers a fundamentally different proposition: extending health span, not just lifespan. Data from Grand View Research projects the global anti-aging market to grow from approximately $72 billion in 2024 at a CAGR of between 7% to 9% through 2032, driven by rising consumer spending on longevity therapeutics, diagnostics, and preventive biologics.
At the same time, academic research from institutions including the Buck Institute, Harvard Medical School, and platforms like bioRxiv is validating the biological mechanisms underlying aging reversal at a pace that would have seemed implausible a decade ago. Breakthroughs in partial reprogramming and epigenetic clock reversal are moving from peer-reviewed theory into early-stage clinical pipelines, reinforcing the long-term scientific credibility of the sector and signaling that longevity medicine is transitioning from fringe to mainstream.
Longevity science has necessity and desire; a global population that is simultaneously living longer and demanding to live better. For funds hunting asymmetric opportunities at the intersection of biology, technology, and an inevitable demographic tide, longevity and anti-aging stocks may be one of the most intellectually compelling and structurally undervalued themes in the market today.
With this context in mind, here are some longevity and anti-aging stocks to buy.
Our Methodology
We used stock screeners to identify longevity and anti-aging stocks with a short percentage of shares outstanding, less than 3%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. To make the list easier to navigate, we ranked the stocks in descending order of their short percentage of shares outstanding as of May 29, 2026.
“Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).”
7 Best Longevity and Anti-Aging Stocks to Buy
7. UnitedHealth Group Incorporated (NYSE:UNH)
Short Percentage of Shares Outstanding: 2.12%
On June 12, subsidiaries of UnitedHealth Group Incorporated (NYSE:UNH), including OptumRx and Emisar Pharma Services, reached an agreement with the Federal Trade Commission to settle allegations that the companies engaged in anticompetitive and unfair rebating practices related to insulin drug pricing. Under the agreement, the matter will be withdrawn from adjudication with respect to the Optum entities while the Commission evaluates a proposed consent agreement intended to fully resolve the claims against them. The Federal Trade Commission ordered that all proceedings involving the Optum respondents be stayed pending the Commission’s review and determination regarding the proposed settlement, representing a significant step toward resolving the regulatory matter.
On June 8, JPMorgan raised its price target on UnitedHealth Group to $466 from $420 while maintaining an Overweight rating on the shares. The firm updated its healthcare services models and increased its valuation outlook, reflecting continued confidence in the company’s long-term earnings potential and market position within the healthcare sector.
Founded in 1974 and headquartered in Minnetonka, Minnesota, UnitedHealth Group operates through UnitedHealthcare for delivering health insurance and Optum for providing pharmacy benefits and care services. It funds healthy aging research through the United Health Foundation and expands Medicare Advantage to support longevity outcomes.
6. Gilead Sciences, Inc. (NASDAQ:GILD)
Short Percentage of Shares Outstanding: 2.07%
On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for Yeztugo 300-mg tablets as a potential once-weekly oral pre-exposure prophylaxis (PrEP) treatment for HIV prevention. The Food and Drug Administration assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 2, 2027, marking an important regulatory milestone for the program. If approved, the therapy could expand Gilead’s HIV prevention portfolio by offering patients a convenient once-weekly oral dosing option.
On June 12, Gilead Sciences, Inc. announced the donation of more than 2,000 vials of its intravenous antiviral therapy remdesivir to the Republic of Uganda to support efforts to combat the ongoing Ebola Bundibugyo virus outbreak. The company stated that the donation reflects its commitment to responding rapidly to global health emergencies and leveraging its extensive experience in infectious disease management. Management emphasized that Gilead is working closely with partners and health authorities to help address the outbreak and support affected communities.
Founded in 1987 and headquartered in Foster City, California, Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics for life-threatening diseases, particularly in virology, oncology, and inflammation. It transforms fatal & chronic conditions (like HIV and Hepatitis C) into highly manageable, long-term states of health.
5. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Short Percentage of Shares Outstanding: 2.05%
On June 2, Deutsche Bank reduced its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 while maintaining a Sell rating on the shares. The revised target reflects the firm’s updated valuation outlook for the company, although the adjustment did not alter its broader investment stance on the stock.
On May 28, Intuitive Surgical, Inc. announced the promotion of Taylor Patton to the role of chief commercial and marketing officer, effective July 1. Patton, who most recently served as global senior vice president of the company’s endoluminal business, will become a member of the executive leadership team and succeed Henry Charlton, who is transitioning to the position of senior vice president of global business operations. Having spent nearly two decades with Intuitive Surgical, Patton has held a variety of leadership roles across commercial operations, marketing, and clinical application engineering, bringing extensive institutional knowledge and industry experience to his new position.
Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical, Inc. produces robotic-assisted, minimally invasive surgery via its flagship da Vinci systems. Its primary involvement focuses on health span by providing less traumatic, more precise surgical options with quicker recovery times, enhancing how well people live as they age.
4. Stryker Corporation (NYSE:SYK)
Short Percentage of Shares Outstanding: 1.63%
On June 12, BofA lowered its price target on Stryker Corporation (NYSE:SYK) to $380 from $450 while maintaining a Buy rating on the shares. The firm cited a softer healthcare utilization environment highlighted by its services team and adopted a more conservative outlook for 2027 across the medical technology sector. The analyst also incorporated assumptions of increased inflationary pressures and reduced margin expansion potential for medtech companies, leading to lower earnings estimates for larger-cap names with exposure to procedure volumes and cost inflation.
On May 26, Stryker Corporation announced the European launch of its Pangea Plating System, a comprehensive plating platform designed to address a broad range of fracture patterns. The first clinical procedure using the system in Europe was successfully completed by Professor Alex Trompeter and his team at St. George’s University Hospital in London. The Pangea Plating System consists of non-active implant devices intended to provide temporary stabilization of bones and bone fragments, along with complementary instrumentation that supports implant fit and offers surgeons greater flexibility in fracture fixation procedures involving both upper and lower extremities.
Founded in 1941 and headquartered in Portage, Michigan, Stryker Corporation is a global medical technology company that designs and manufactures innovative orthopedic implants, surgical equipment, and neurotechnology. The company provides joint replacements, robotic surgical assistance, and spinal technologies that restore mobility and dramatically enhance the quality of life for aging individuals.
3. Eli Lilly and Company (NYSE:LLY)
Short Percentage of Shares Outstanding: 1.10%
On June 16, Austin-based neuroscience company 4E Therapeutics announced that it had been acquired by Eli Lilly and Company (NYSE:LLY). 4E Therapeutics is developing a pipeline of orally available MNK inhibitors designed to treat chronic pain by targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons. Financial terms of the transaction were not disclosed.
On the same day, Eli Lilly and Company reported new Phase 1 data from the AJX-101 study showing that its investigational type II JAK2 inhibitor demonstrated a favorable safety profile and encouraging clinical activity in patients with myelofibrosis who had previously failed treatment with a type I JAK2 inhibitor. The therapy was specifically designed to selectively target the type II conformation of the JAK2 kinase, potentially offering a differentiated treatment option for patients who develop resistance to currently available therapies. Lilly recently added the program to its development pipeline through an acquisition, further expanding its oncology portfolio.
Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company is a global pharmaceutical leader focused on developing innovative medicines for diabetes, obesity, cancer, immunology, and neuroscience. The company has emerged as one of the key players in the longevity and healthy-aging space through its groundbreaking metabolic disease treatments, while continuing to invest heavily in next-generation therapies across multiple high-growth areas of healthcare.
2. Novo Nordisk A/S (NYSE:NVO)
Short Percentage of Shares Outstanding: 0.51%
On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares.
Earlier, on June 11, Novo Nordisk A/S announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency approved the Wegovy pill as an adjunct to a reduced-calorie diet and increased physical activity. The approval makes the therapy the first oral GLP-1 receptor agonist authorized for weight management in adults living with obesity or overweight who also have at least one weight-related medical condition. The decision was supported by data from the Phase 3 OASIS 4 clinical trial and expands Novo Nordisk’s obesity treatment portfolio by offering patients a non-injectable alternative to existing therapies.
Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S is a global healthcare company specializing in chronic conditions like diabetes and obesity. It is primarily known for developing lifesaving GLP-1 therapies like Ozempic and Wegovy, but it also targets the underlying metabolic and cardiovascular diseases that reduce lifespan.
1. Novartis AG (NYSE:NVS)
Short Percentage of Shares Outstanding: 0.24%
On June 12, Novartis AG (NYSE:NVS) presented results from the RemIND trial at the European Academy of Allergy and Clinical Immunology Congress, demonstrating that Rhapsido achieved its primary endpoints across the three most common chronic inducible urticaria subtypes. The therapy became the first treatment to show efficacy in a global Phase III clinical trial for chronic inducible urticaria, with higher rates of complete responses observed by week 12 and clinical benefits emerging as early as week 2 in two of the subtypes. The findings suggest that Rhapsido may offer durable symptom relief for patients whose condition remains inadequately controlled despite treatment with second-generation H1-antihistamines.
On June 10, Novartis AG announced a multi-year collaboration with Orionis Biosciences to discover and develop molecular glue therapeutics targeting challenging disease pathways across multiple therapeutic areas. The agreement expands the companies’ existing relationship and will combine Orionis’ Allo-Glue platform and AI-driven discovery capabilities with Novartis’ drug development expertise to accelerate target identification, ligase profiling, and molecular glue optimization. Under the terms of the collaboration, Orionis will receive a $40 million upfront payment and may earn up to $1.4 billion in research, development, and commercial milestone payments, in addition to tiered royalties on future product sales.
Incorporated in March 1996 and headquartered in Basel, Switzerland, Novartis AG is a multinational pharmaceutical corporation that researches and develops innovative prescription medicines. The company explores the mTOR pathway via the rapamycin (sirolimus) class of compounds, aiming to delay age-related diseases and extend health span.
READ NEXT: 10 Under-the-Radar AI Stocks to Buy in 2026 and Top 10 Stocks That Members of Congress Own.
